ApoB, LDL-C, Lp(a), and insulin as risk factors for cardiovascular disease [AMA 43 sneak peek]

TL;DR

Insulin levels can impact lipid parameters, such as APOB and LDL-C, and contribute to the risk of atherosclerotic cardiovascular disease (ASCVD).

Transcript

hey everyone welcome to the drive podcast I'm your host Peter attia here welcome to another AMA how you doing I'm doing well although looking at your T-shirt and realizing that you probably bought that at Coda I'm a little less good because I'm realizing I somehow missed that shirt and didn't buy one myself ah it's a good looking shirt and we didn'... Read More

Key Insights

• 🅰️ Hyperinsulinemia, commonly seen in type 2 diabetes, is associated with a higher risk of ASCVD.
• *️⃣ Increased expression of APOC3 due to hyperinsulinemia leads to elevated levels of triglycerides and APOB, contributing to ASCVD risk.
• ❓ Hyperinsulinemia can also cause endothelial dysfunction, further promoting the development of atherosclerosis.
• *️⃣ APOB is a better predictor of ASCVD risk than LDL-C alone, as it includes other atherogenic particles like VLDL and LP little a.
• 🅰️ Insulin levels and lipid parameters should be monitored to assess ASCVD risk even in individuals without type 2 diabetes.
• *️⃣ Strategies to reduce insulin levels, improve lipid parameters, and prevent endothelial dysfunction are important in managing ASCVD risk.

Questions & Answers

Q: Are there relationships between insulin levels and lipid parameters in ASCVD?

Yes, insulin levels, particularly in cases of hyperinsulinemia, can affect lipid parameters. Increased insulin can lead to higher levels of APOC3, which blocks lipoprotein lipase and results in elevated levels of triglycerides and APOB.

Q: How does hyperinsulinemia impact the risk of ASCVD?

Hyperinsulinemia is associated with a greater risk of developing ASCVD. It affects lipid parameters, promotes the expression of APOC3, leads to increased levels of triglycerides, APOB, and impaired endothelial function, all of which contribute to atherosclerosis development.

Q: What is the role of APOB and LDL-C in ASCVD?

APOB is a better predictor of ASCVD risk as it encompasses not only LDL-C but also other atherogenic particles like VLDL and LP little a. However, LDL-C can still provide some insight into risk assessment if APOB levels are unknown.

Q: How can insulin influence endothelial dysfunction in ASCVD?

Insulin, particularly in cases of hyperinsulinemia, can promote endothelial dysfunction, which leads to increased permeability of APOB particles through the endothelium. This contributes to the progression of atherosclerosis.

Key Insights:

• Hyperinsulinemia, commonly seen in type 2 diabetes, is associated with a higher risk of ASCVD.
• Increased expression of APOC3 due to hyperinsulinemia leads to elevated levels of triglycerides and APOB, contributing to ASCVD risk.
• Hyperinsulinemia can also cause endothelial dysfunction, further promoting the development of atherosclerosis.
• APOB is a better predictor of ASCVD risk than LDL-C alone, as it includes other atherogenic particles like VLDL and LP little a.
• Insulin levels and lipid parameters should be monitored to assess ASCVD risk even in individuals without type 2 diabetes.
• Strategies to reduce insulin levels, improve lipid parameters, and prevent endothelial dysfunction are important in managing ASCVD risk.
• Further research is needed to fully understand the mechanisms through which insulin affects ASCVD risk and to develop targeted interventions.

Summary & Key Takeaways

• Insulin levels, especially in cases of hyperinsulinemia, have been linked to worse outcomes in ASCVD, such as an increased risk of developing type 2 diabetes.

• Hyperinsulinemia affects lipid parameters by increasing the expression of APOC3, which blocks the action of lipoprotein lipase, leading to elevated levels of triglycerides and APOB.

• Insulin also plays a role in endothelial dysfunction, which can contribute to the progression of ASCVD.